Xarelto has been linked to an increased risk of internal bleeding that may become uncontrolled and quite serious, in some cases leading to death. The risks of internal bleeding may be greater than what users were led to believe, especially with the lack of an antidote to stop uncontrolled internal bleeding, as other anti-coagulants have. Due to the risk of dangerous bleeding from Xarelto, physicians and safety experts question whether Xarelto offers benefits over other blood thinners. Read more about the increase in internal bleeding risk from Xarelto below.
Xarelto (Rivaroxaban) is an anticoagulant, also known as a blood thinner, which is often prescribed to patients who suffer from atrial fibrillation or have had hip replacement surgery, heart attacks, or strokes. The goal of blood thinners is to prevent dangerous blood clots from forming and obstructing vital blood flow to the organs and brain. Xarelto is one of a newer class of oral anticoagulants that was developed and manufactured by Bayer and Janssen Pharmaceuticals. It was approved for use by the FDA in 2011 after following a fast-track regulatory review. At the time, no antidote was known to stop Xarelto bleeding, leaving some physicians wondering why Xarelto was ever approved for widespread use.
In 2013, Xarelto manufacturers were sent a warning letter by the FDA for using false or misleading information in their advertisements and promotional materials. The FDA also warned that Xarelto manufacturers were minimizing the risks associated with using their drug and making false and misleading claims regarding its effectiveness. To date, there is little evidence to suggest that Xarelto offers clear advantages over warfarin, the blood thinner traditionally prescribed to prevent dangerous blood clots. Warfarin offers one clear advantage over Xarelto - a simple shot of Vitamin K will stop bleeding immediately. Once Xarelto bleeding begins, there is no reliable way to stop it.
Misleading advertising regarding the risks associated with Xarelto internal bleeding is a grave problem. Adverse event reports made to the FDA show that Xarelto causes serious internal bleeding in a higher percentage of patients than do comparable blood thinners. Also worrying is the fact that younger, healthier patients are suffering from Xarelto internal bleeding. And without a clear and reliable method for reversing this problem, Xarelto bleeding can be severe and even fatal.
The leading injuries named in Xarelto lawsuits including internal bleeding and hemorrhagic stroke.
Internal bleeding and hemorrhagic stroke are side effects faced by any patient taking Xarelto. The most common patients suffering from these conditions are younger patients (60s) who took the drug following joint replacement surgery, according to FDA records.
There are multiple layers to that answer. One on side, some critics blame the FDA regulatory process which fast-tracked this drug without thorough testing. Early research presented to the FDA showed Xarelto offered benefits over warfarin, such as convenience due to the fact that patients would not need to have their blood tested regularly. On the other hand, many experts say the fault ultimately lies with the drug companies, Bayer and Janssen Pharmaceuticals, because the companies purposely glossed over the risks associated with Xarelto bleeding, instead focusing on its supposed benefits. Now experts say Xarelto may not have benefits that outweigh its risks.
If you suffered internal bleeding or a stroke while taking Xarelto, you may qualify to file a Xarelto lawsuit. For more information on filing a Xarelto bleeding lawsuit on behalf of yourself or a loved one, contact our firm for a Xarelto lawsuit case review.
While Xarelto bleeding lawsuits are time sensitive, persons who took Xarelto and suffered side effects such as internal bleeding or hemorrhagic stroke are still eligible to file a Xarelto lawsuit now. To ask an attorney handling Xarelto lawsuit claims about relevant time limits for your case, contact our firm.
For more information, please visit our Xarelto Bleeding website.
A leader in cancer research at Harvard University asserts that perhaps 10,000 cases of ovarian cancer can be blamed each year on perineal talc use in the US. Despite the existence of evidence that talc-based products are dangerous and can cause cancer, talc is not regulated in the US. The American Cancer Society estimates that in 2013, about 22,240 new cases of ovarian cancer will be diagnosed, while 14,030 women will die as a result of ovarian cancer in the US.
Roundup weed killer, manufactured by Monsanto, uses a chemical called glyphosate, which the World Health Organization labeled as a probable carcinogen in 2015. Roundup is the most popular of all glyphosate-based herbicides. As little as 8 hours of Roundup exposure has been linked to an increased risk of non-Hodgkin lymphoma, multiple myeloma, and leukemia. Millions of gardeners, landscapers, farmers and others have been exposed to Roundup cancer risks.
Physiomesh is a form of surgical mesh that has been used in hernia repair surgeries. Ethicon Physiomesh was used in ventral hernia repair and has been pulled from the market due to a high failure rate. Persons with Ethicon Physiomesh have experienced an array of complications that include pain, infection, hernia recurrence, adhesion or scar-tissue buildup, intestinal blockage, bleeding, perforation, organ damage, and the need for revision surgery.